 | Up a level |
2017
Scheffler, M., Koleczko, S., Teixido, C., El Bairi, K., Morales Espinosa, D., Chatterjee, S., Rolfo, C., Koehler, J., Thommen, D., Ortiz-Cuaran, S., Abdulla, D. S. Y., Brandes, V., Bhaumik, S., Frizzera Borges Bognar, C. L., Calles, A., Holzem, A. and Wolf, J. (2017). An international platform representing expectations and experiences of young investigators in cancer research - [VI:N]. Oncol. Res. Treat., 40. S. 259 - 260. BASEL: KARGER. ISSN 2296-5262
2016
Reguart, N., Pare, L., Gimenez-Capitan, A., Teixido, C., Galvan, P., Viteri, S., Rodriguez, S., Peg, V., Aldeguer, E., Ovalle, E., Vinolas, N., Merkelbach-Bruse, S., Lopez-Rios, F., Rosell, R., Molina-Vila, M. A. and Prat, A. (2016). Automated nCounter-based assay for identifying clinically relevant ALK, ROS1 and RET rearrangements in advanced non-small cell lung cancer (NSCLC). Ann. Oncol., 27. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
2014
Michels, S., Gardizi, M., Schultheis, A., Scheffler, M., Karachaliou, N., Teixido, C., Heukamp, L., Merkelbach-Bruse, S., Thurat, M., Nogova, L., Bos, M., Mattonet, C., Grohe, C., Sebastian, M., Thomas, M., Reck, M., Stahel, R., Pirker, R., Zoechbauer-Mueller, S., Groen, H., Dingemanns, A. -M, Smit, E., Thomas, R., Buettner, R., Massuti, B., Rosell, R. and Wolf, J. (2014). EUCROSS: A phase II trial to evaluate efficacy and safety of crizotinib treatment in advanced adenocarcinoma of the lung harbouring ROS1 translocations. Oncol. Res. Treat., 37. S. 65 - 66. BASEL: KARGER. ISSN 2296-5262
Scheffler, M., Schultheis, A., Michels, S., Teixido, C., Hartmann, W., Merkelbach-Bruse, S., Sebastian, M., Serke, M., Kropf-Sanchen, C., Wittersheim, M., Puetz, K., Binot, E., Schildhaus, H. -U., Heukamp, L. C., Rosell, R., Buettner, R. and Wolf, J. (2014). ROS1 rearrangement in non-small cell lung cancer (NSCLC): Prognostic and predicitve impact and genetic variability. Oncol. Res. Treat., 37. S. 66 - 67. BASEL: KARGER. ISSN 2296-5262